Khiron Secures Endorsement from the Leading Palliative Care Association in Colombia

Exclusive agreement represents significant initial milestone related to Khiron’s strategy of meeting the medical needs of 4 million palliative care patients in Latin America

TORONTO, Oct. 26, 2018 /CNW/ - Khiron Life Sciences Corp. (Khiron” or the "Company") (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), an integrated medical cannabis company with its core operations in Colombia, announced today that the Company has signed an exclusive agreement with the Colombian Association of Palliative Care (ACCP), the leading network of pain and palliative care specialists in Colombia.

The Latin American Association of Palliative Care (ALCP) estimates 4 million people need palliative care treatment within the Latin American market. This agreement forms the initial step towards addressing the medical needs of these individuals and enables Khiron to provide doctors and caregivers with direct access to specialized e-learning platforms, information, research, and educational resources about extract-based medical cannabis treatment alternatives. As part of this agreement, Khiron will be the exclusive medical cannabis company marketing to, and participating in, ACCP events and activities in Colombia.

Dr. Maria Fernanda Arboleda, Medical Director of Khiron stated, "As a pain and palliative care physician, I have learned from my clinical experience that medical cannabis can be utilized effectively as a complementary therapy in reducing pain and related symptoms of palliative care patients. This important relationship with the Colombian Association of Palliative Care will allow us to support the use of medical cannabis in this population and improve the standards of care and patients’ safety in Colombia."

Dr. Claudia Buitrago, President of the ACCP stated, "We are convinced that working with Khiron will bring educational tools that are fundamental to our medical associates being able to prescribe medical cannabis and allows them to have a higher degree of confidence that their recommendations are responsible and informed."

The field of palliative care in Colombia is at the development stage. Doctors, staff and interdisciplinary teams are working to inform and train specialist care providers, with the objective of reducing the pain and associated symptoms of palliative care patients. The recent International Palliative Care Congress, held in Medellin, Colombia, attracted more than 400 doctors and specialists in pain and palliative care, and included a presentation by Dr. Arboleda.
Dr. Maria Fernanda Arboleda is the co-author of *Cannabis in Palliative Care: current challenges and practical recommendations*, a comprehensive analysis of the role of Cannabinoid-based medicines in palliative care treatment. This review, which was recently published in the Annals of Palliative Medicine, can be found at [http://apm.amegroups.com/article/view/20097/21242](http://apm.amegroups.com/article/view/20097/21242)

**About The Colombian Association of Palliative Care (ACCP)**

Founded in 1996, The Palliative Care Association of Colombia is an non-profit interdisciplinary association of qualified professionals that have experience in the clinical aspects, research, and organization of Palliative Care with a powerful drive to come together to work towards the development and the implementation of palliative care in all levels of health care in Colombia.

The ACCP leads changes in palliative care access, and provides scientific and humanized quality care, providing all universities with palliative care training programs, as well as in undergraduate medicine, nursing and psychology. For information visit [www.paliativoscolombia.org](http://www.paliativoscolombia.org)

**About Khiron Life Sciences Corp.**

Khiron Life Sciences Corp. (TSXV: KRHN, OTCQB: KHRNF, Frankfurt: A2JMZC) ("Khiron" or the "Company") is positioned to be the dominant integrated medical cannabis company in Latin America. Khiron has core operations in Colombia and is fully licensed in the country for the cultivation, production, domestic distribution, and international export of both tetrahydrocannabinol (THC) and cannabidiol (CBD) medical cannabis. In May 2018, Khiron listed on the TSX Venture Exchange, becoming one of the first Colombian based medical cannabis company to trade on any exchange globally.

With a focused regional strategy and patient oriented approach, the Company combines global scientific expertise, agricultural advantages, branded product market entrance experience and education to drive prescription and brand loyalty to address priority medical conditions such as chronic pain, epilepsy, depression and anxiety in the Latin American market of over 620 million people. Khiron is led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced executive team, and a knowledgeable Board of Directors that includes former President of Mexico, Vicente Fox.

Further information on Khiron Life Sciences can be found at [www.khiron.ca](http://www.khiron.ca).

**Forward-Looking Statements**

This press release may contain certain forward-looking information and statements ("forward-looking information") within the meaning of applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. Readers are cautioned to not place undue reliance on forward-looking information. Actual results and developments may differ materially from those contemplated by these statements. Khiron undertakes no obligation to comment analyses, expectations or statements made by third-parties in
respect of Khiron, its securities, or financial or operating results (as applicable). Although Khiron believes that the expectations reflected in forward-looking information in this press release are reasonable, such forward-looking information has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond Khiron's control, including the risk factors discussed in Khiron's Filing Statement which is available on Khiron's SEDAR profile at www.sedar.com. The forward-looking information contained in this press release is expressly qualified by this cautionary statement and are made as of the date hereof. Khiron disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.

SOURCE Khiron Life Sciences Corp.

For further information: Investor Contacts: Chris Naprawa, President, T: +1 (416) 705-1144, E: cnaprawa@khiron.ca; Darren Collins, Chief Financial Officer, T: +1 (705) 527-3564, E: dcollins@khiron.ca; Media Contact: Jon Packer, Vice President, Communications, T: +1 (416) 543-9179, E: jpacker@khiron.ca